Geographic and Product Data

9 Months Ended

Oct. 03, 2014

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

Note 9 — Geographic and Product Data

The Company markets and sells its products in over 60 countries and has manufacturing sites in the United States and Switzerland. Other than the United States, Japan, Korea, China, Spain, and France, the Company does not conduct business in any country in which its sales exceed 5% of consolidated sales. Sales are attributed to countries based on location of customers. The composition of the Company’s net sales to unaffiliated customers is set forth below (in thousands):

	Three Months Ended				Nine Months Ended
	October 3,		September 27,		October 3,		September 27,
	2014		2013		2014		2013
Japan	$	4,792	$	4,040	$	14,349	$	13,427
United States		2,875		2,993		8,676		9,388
China		2,915		2,275		7,675		6,575
Korea		1,098		1,982		5,671		5,851
Spain		1,178		1,012		4,270		3,466
France		820		595		2,956		1,722
Other		4,510		4,209		14,817		12,842
Total	$	18,188	$	17,106	$	58,414	$	53,271

100% of the Company’s sales are generated from the ophthalmic surgical product segment and therefore the Company operates as one operating segment for financial reporting purposes. The Company’s principal products are implantable Collamer lenses (“ICLs”) used in refractive surgery and intraocular lenses (“IOLs”) used in cataract surgery. The composition of the Company’s net sales by product line is as follows (in thousands):

	Three Months Ended				Nine Months Ended
	October 3,		September 27,		October 3,		September 27,
	2014		2013		2014		2013
ICLs	$	10,640	$	10,725	$	35,052	$	32,616
IOLs		5,763		5,322		18,804		17,533
Core products		16,403		16,047		53,856		50,149
Other Surgical Products		1,785		1,059		4,558		3,122
Total	$	18,188	$	17,106	$	58,414	$	53,271

The Company sells its products internationally, which subjects the Company to several potential risks, regional/country economic conditions and regulatory requirements, including fluctuating foreign currency exchange rates (to the extent the Company’s transactions are not in U.S. dollars), regulation of fund transfers by foreign governments, the United States and foreign export and import duties and tariffs, and political instability.